Infinity Pharmaceuticals (NASDAQ: INFI) and Mesoblast limited (OTCMKTS:MBLTY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.
Earnings & Valuation
This table compares Infinity Pharmaceuticals and Mesoblast limited’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Infinity Pharmaceuticals||N/A||N/A||-$55.73 million||($1.40)||-0.86|
Insider and Institutional Ownership
67.5% of Infinity Pharmaceuticals shares are held by institutional investors. 6.8% of Infinity Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares Infinity Pharmaceuticals and Mesoblast limited’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and target prices for Infinity Pharmaceuticals and Mesoblast limited, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Mesoblast limited has a consensus price target of $14.00, suggesting a potential upside of 13.54%. Given Mesoblast limited’s stronger consensus rating and higher possible upside, analysts plainly believe Mesoblast limited is more favorable than Infinity Pharmaceuticals.
Mesoblast limited beats Infinity Pharmaceuticals on 5 of the 8 factors compared between the two stocks.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.
About Mesoblast limited
Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.